Literature DB >> 10387142

Effect of electrode configuration and capacitor size on internal atrial defibrillation threshold using leads currently used for ventricular defibrillation.

R Neri1, P Palermo, A S Cesario, D Baragli, E Amici, M T Laudadio, A De Rosa, F DeSeta, L Mongeon, G Gambelli.   

Abstract

BACKGROUND: Previous studies have shown that endocardial atrial defibrillation, using lead configurations specifically designed for ventricular defibrillation, is feasible but the substantial patient discomfort might prevent the widespread use of the technique unless significant improvements in shock tolerability are achieved. It has been suggested that the peak voltage or the peak current but not the total energy delivered determines the patient pain perception and therefore, lower defibrillating voltage and current achieved with modifications in lead and waveforms may increase shock tolerability. This study was undertaken to evaluate the effect, on the atrial defibrillation threshold (ADFT), of the addition of a patch electrode (mimicking the can electrode) to the right ventricle (RV)-superior vena cava (SVC) lead configuration. The influence of capacitor size on ADFT using the RV-SVC+skin patch configuration was also assessed.
METHODS: In 10 patients (pts) (Group 1) cardioversion thresholds were evaluated using biphasic shocks in two different configurations: 1) right ventricle (RV) to superior vena cava (SVC); 2) RV to SVC+skin patch. In a second group of twelve patients (Group 2) atrial defibrillation thresholds of biphasic waveforms that differed with the total capacitance (90 or 170 microF) were assessed using the RV to SVC+skin patch configuration.
RESULTS: In Group 1 AF was terminated in 10/10 pts (100 %) with both configurations. There was no significant difference in delivered energy at the defibrillation threshold between the two configurations (7.1 +/- 5.1 J vs 7.1 +/- 2.6 J; p < 0.05). In group 2 AF was terminated in 12/12 pts (100%) with both waveforms. The 170 microF waveform provided a significantly lower defibrillating voltage (323.7 +/- 74.6 V vs 380 +/- 70.2 V; p < 0.03) and current (8.1 +/- 2.7 A vs 10.0 +/- 2.3 A; p < 0.04) than the 90 microF waveform. All pts, in both groups, perceived the shock of the lowest energy tested (180 V) as painful or uncomfortable.
CONCLUSIONS: The addition of a patch electrode to the RV-SVC lead configuration does not reduce the ADFT. Shocks from larger capacitors defibrillate with lower voltage and current but pts still perceive low energy subthreshold shocks as painful or uncomfortable.

Entities:  

Mesh:

Year:  1999        PMID: 10387142     DOI: 10.1023/a:1009821514753

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  18 in total

1.  Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.

Authors:  M Grogan; H C Smith; B J Gersh; D L Wood
Journal:  Am J Cardiol       Date:  1992-06-15       Impact factor: 2.778

2.  Implantation of an arrhythmia management system for ventricular and supraventricular tachyarrhythmias.

Authors:  W Jung; B Lüderitz
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

3.  Internal cardioversion of chronic atrial fibrillation in patients.

Authors:  R Neri; P Palermo; A S Cesario; D Baragli; E Amici; G Gambelli
Journal:  Pacing Clin Electrophysiol       Date:  1997-09       Impact factor: 1.976

4.  Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception.

Authors:  G Tomassoni; K H Newby; M M Kearney; M J Brandon; H Barold; A Natale
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

5.  Effect of capacitor size and pathway resistance on defibrillation threshold for implantable defibrillators.

Authors:  C D Swerdlow; R M Kass; P S Chen; C Hwang; S Raissi
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

6.  Efficacy of a single-lead unipolar transvenous defibrillator compared with a system employing an additional coronary sinus electrode. A prospective, randomized study.

Authors:  P J Kudenchuk; G H Bardy; G L Dolack; J E Poole; R Mehra; G Johnson
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

7.  Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans.

Authors:  F D Murgatroyd; A K Slade; S M Sopher; E Rowland; D E Ward; A J Camm
Journal:  J Am Coll Cardiol       Date:  1995-05       Impact factor: 24.094

8.  Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation.

Authors:  G M Ayers; C A Alferness; M Ilina; D O Wagner; W A Sirokman; J M Adams; J C Griffin
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors:  G C Flaker; J L Blackshear; R McBride; R A Kronmal; J L Halperin; R G Hart
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

10.  Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations.

Authors:  S Saksena; A Prakash; L Mangeon; S Varanasi; T Kolettis; P Mathew; P De Groot; R Mehra; R B Krol
Journal:  Am J Cardiol       Date:  1995-11-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.